Job Description:
We are seeking a motivated and collaborative team member who would like to get into the company at an early stage. You will be the second computational member our team, responsible for developing novel computational analyses for our proteomics- and NGS-driven screening programs, as well as expanding and maintaining central data analysis pipelines. Job Responsibilities:
Additional Info:
FogPharma was founded by renowned life scientist, inventor, pharmaceutical entrepreneur, and biotech company builder Gregory Verdine, with the goal of radically improving treatment outcomes in cancer patients by targeting disease drivers previously believed to be “undruggable.” The company is pioneering a new drug modality, cell-penetrating miniproteins, invented by Verdine and his team members at Harvard University and FogPharma to provide drugs that uniquely combine the broad target-engagement power of biologic drugs with the cell-entry capabilities of small molecules. The lead program, direct-acting beta-catenin antagonists, is expected to provide first-in-class drugs having a unique profile, acting both to ablate multiple intractable cancer types harboring activating mutations in the Wnt pathway, and to also stimulate T-cell infiltration into many solid tumors that at present are poorly responsive to immunotherapy. Additional programs targeting other highly validated targets are also being pursued by the company. We are a vibrant and driven group of scientists and science lovers, with a strong entrepreneurial spirit, and deeply committed to our mission of adding years to life and life to years through the creation of transformative new medicines. [Click Here to Access the Original Job Post]
We are seeking a motivated and collaborative team member who would like to get into the company at an early stage. You will be the second computational member our team, responsible for developing novel computational analyses for our proteomics- and NGS-driven screening programs, as well as expanding and maintaining central data analysis pipelines. Job Responsibilities:
- Work closely with other scientists to develop statistical analyses and visualizations to support decision making in proteomics- and NGS-driven drug discovery projects
- Develop and maintain data analysis pipelines to be used by other scientist for routine data analysis
- Independently research methods in statistics, proteomics, and data analysis as needed
- Serve as team expert for computational and statistical topics
- PhD in Science or Engineering with 3+ years of work experience, or MS with 8+ years of work experience
- Strong programming and quantitative skills, knowledge of statistics
- Demonstrated experience developing novel analyses to address challenging scientific problems
- Familiarity with R (preferred), Python, C/C++, or similar; ability to self-teach new languages and tools
- Interest in statistics, modeling, machine learning, and data visualization
- Experience in proteomics, bioinformatics, NGS, and mass spectrometry is especially valuable
- Knowledge of SQL and ability to design and establish databases that integrate data from multiple sources is a plus
- Independence, initiative, willingness to take on responsibility and make key decisions that have a significant impact on the company
- Ability to work in a team, communicate with technical and non-technical staff, and give/receive constructive feedback
- Strong organizational and documentation skills, especially regarding database architecture and software development (version control, code annotation, etc.)
Requeriments :
Skills :
- Bioinformatics
- Machine Learning
- Modeling
- Next Generation Sequencing
- Programing in C
- Programing in C++
- Programing in Python
- Programing Skills
- Programming in R
- SQL
- Statistics
- Version Control
Areas :
Additional Info:
FogPharma was founded by renowned life scientist, inventor, pharmaceutical entrepreneur, and biotech company builder Gregory Verdine, with the goal of radically improving treatment outcomes in cancer patients by targeting disease drivers previously believed to be “undruggable.” The company is pioneering a new drug modality, cell-penetrating miniproteins, invented by Verdine and his team members at Harvard University and FogPharma to provide drugs that uniquely combine the broad target-engagement power of biologic drugs with the cell-entry capabilities of small molecules. The lead program, direct-acting beta-catenin antagonists, is expected to provide first-in-class drugs having a unique profile, acting both to ablate multiple intractable cancer types harboring activating mutations in the Wnt pathway, and to also stimulate T-cell infiltration into many solid tumors that at present are poorly responsive to immunotherapy. Additional programs targeting other highly validated targets are also being pursued by the company. We are a vibrant and driven group of scientists and science lovers, with a strong entrepreneurial spirit, and deeply committed to our mission of adding years to life and life to years through the creation of transformative new medicines. [Click Here to Access the Original Job Post]